{"id":"W3188660209","doi":"10.1007/s40273-021-01068-9","title":"Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame","funders":"Karyopharm Therapeutics","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Pomalidomide; Progression-free survival; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001608948,0.0004009175,0.001051463,0.0001924809,0.00009911651,0.00004234405,0.0002469847,0.0001551538,0.000291371],"category_scores_gemma":[0.001742136,0.0003124073,0.0003176059,0.000377435,0.000123561,0.0001160308,0.00007679612,0.0005159872,0.00005569553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005279119,"about_ca_system_score_gemma":0.0006536098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001588543,"about_ca_topic_score_gemma":0.0002900478,"domain_scores_codex":[0.9962172,0.001077565,0.001017151,0.0008069391,0.0003058228,0.0005753124],"domain_scores_gemma":[0.9924096,0.00592417,0.0003299675,0.0008067557,0.0001874407,0.0003420647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8549675,0.007396679,0.02016149,0.0001521952,0.0009463904,0.0007409764,0.0004239113,0.001854321,0.04667946,0.000008047439,0.001059096,0.06560992],"study_design_scores_gemma":[0.5924601,0.001333287,0.01423207,0.0002869325,0.0002898108,0.000008229988,0.00009371576,0.09120557,0.297426,0.00001049968,0.002398255,0.0002555288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915673,0.0003514643,0.0001261077,0.00071879,0.0003333973,0.004433547,0.001900407,0.00005421301,0.0005147599],"genre_scores_gemma":[0.9948769,0.0003406153,0.0003872311,0.0004410406,0.0003107075,0.0004167899,0.003048348,0.00006366178,0.0001147678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2625074,"threshold_uncertainty_score":0.9999328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08245124933852116,"score_gpt":0.3953296840196429,"score_spread":0.3128784346811218,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}